Pyxis Oncology (PYXS)
(Delayed Data from NSDQ)
$4.15 USD
-0.02 (-0.48%)
Updated May 17, 2024 04:00 PM ET
After-Market: $4.17 +0.02 (0.48%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PYXS 4.15 -0.02(-0.48%)
Will PYXS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PYXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PYXS
Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates
Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect?
PYXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Pyxis Oncology (PYXS) Rating Upgrade to Buy
Down -15.56% in 4 Weeks, Here's Why You Should You Buy the Dip in Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Other News for PYXS
Wall Street Analysts Are Bullish on Top Healthcare Picks
Buy Rating Affirmed for Pyxis Oncology on Strong Financials and Promising Clinical Progress
Buy Rating Affirmed for Pyxis Oncology on Robust Clinical Pipeline and Solid Financials
Pyxis Oncology GAAP EPS of -$0.06, revenue of $16.1M
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024